ARE Alexandria Real Estate Equities Earnings and EPS analysis

EPS in 2025 (TTM): -$0.13

Last Report Period Date: Jun 30, 2025

As of August 2025, ARE's current EPS stands at -$0.13, according to the latest financial reports. For the year 2024, the company recorded an earnings per share (EPS) of $1.8, which marks an increase compared to its EPS of $0.54 in 2023. ARE reported an EPS of -$0.64 for the quarterly report ending on Jun 30, 2025.

ARE earnings history

Historical annual and quarterly earnings per share (EPS) data for Alexandria Real Estate Equities
EPS (TTM)
-$0.13
EPS Growth YoY (Quarterly)
-356%
EPS (Quarterly)
-$0.64
EPS Growth (Quarterly)
-814.3%

For 2024, Alexandria Real Estate Equities's EPS was $1.8, an increase of 233.3% from $0.54 in 2023. For the fiscal quarter that ended on Jun 30, 2025, the per-share earnings was -$0.64, showing a 356% decrease from the same quarter last year. For the twelve months ending June 2025, the EPS is -$0.13. For the year 2023, the yearly earnings per share was $0.54, marking a decrease of 83% from 2022.

ARE EPS growth

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
-356%
EPS growth YoY
233.3%
EPS growth 3Y avg
-22.3%
EPS growth 5Y avg
-10.5%

Alexandria Real Estate Equities has registered a decrease in EPS of 356% during the last 12 months (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of -22.3% per year for the last three years. Alexandria Real Estate Equities had an average annual EPS growth rate of -10.5% during the last 5 years. A 10-year view shows that ARE has seen an average EPS growth of 5.9% per year.

ARE Earnings Waterfall

Breakdown of revenue, profit and net income for Alexandria Real Estate Equities

ARE Earnings vs Peers

What are the earnings of ARE compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
ILMN Illumina Inc 11.94 -4.8% N/A N/A
PFE Pfizer Inc 13.01 273.7% -28.7% -13.2%
BMY Bristol Myers Squibb Co 18.45 -213.7% N/A N/A
AMGN Amgen Inc 23.4 -39.3% -9.7% -10.1%
GILD Gilead Sciences Inc 23.65 -91.6% -57.5% -38.3%
LLY ELI LILLY & Co 40.76 102.1% 24.1% 5.7%
ALNY Alnylam Pharmaceuticals Inc N/A 38.1% N/A N/A
ARE Alexandria Real Estate Equities Inc N/A 233.3% -22.3% -10.5%

All data is based on quarterly TTM periods, unless otherwise specified.